Saitama Medical University International Medical Center Selects MRIdian® MRI-Guided Radiation Therapy System

CLEVELAND, July 19, 2022 /PRNewswire/ — ViewRay, Inc. (NASDAQ: VRAY) today announced that Saitama Medical University International Medical Center has purchased an MRIdian MRI-guided radiation therapy system to complement its new comprehensive cancer center in Yamane, in the city of Hidaka. The MRIdian System Will Enable Saitama Medical University to Offer Advanced MRI-Guided Radiation Therapy Technology to Cancer Patients Seeking Personalized Treatment for Pancreatic, Prostate, Lung, Liver, Breast and Oligometastatic Cancers .

Saitama Medical University International Medical Center is set to install its MRIdian system in December 2022, with the first treatments for patients beginning in early 2023. The center looks forward to using MRIdian’s real-time tracking and automated beam-triggering technology to support aggressive Stereotactic Body Radiation Therapy (SBRT) and treat complex cases. Indications of particular interest to researchers at Saitama Medical University are the pancreas and prostate, with a desire to participate in international multicenter research hospital trials.

“Our focus on high quality medical treatment with an emphasis on patient safety and satisfaction makes MRIdian a perfect complement to our cancer treatment offerings,” said Dr. Shingo Kato, Professor and Director, Department of Radiation Oncology. “The ability to visualize and track the tumor and control the beam in real time under MRI guidance and tailor treatment delivery to the unique anatomical and tumor changes in each patient fully supports our patient-centered approach to care and will be of significant benefit to patients throughout the region.

Saitama Medical University International Medical Center was established in April 2007 with the aim of contributing to regional and Japanese medicine, aiming to create an internationally competitive world-class hospital. In February 2015 Saitama Medical University International Medical Center became the first teaching hospital in Japan to acquire Joint Commission International (JCI) certification, demonstrating adherence to international quality standards for medical quality and safety. The motto of the Comprehensive Cancer Center is to treat cancer patients holistically, not to treat the tumor itself.

The MRIdian system provides oncologists with exceptional anatomical visualization through diagnostic-quality MRI images and the ability to tailor a radiation treatment plan to the targeted cancer with the patient on the table. This combination allows physicians to set narrow treatment margins to avoid unnecessary radiation exposure to vulnerable organs at risk and healthy tissues and allows the delivery of ablative radiation doses in five treatment sessions or less, without relying on implanted markers. By providing real-time, continuous tracking of the target and organs at risk, MRIdian enables automatic radiation beam triggering if the target moves outside of user-defined margins. This allows the prescribed dose to be delivered to the target, while sparing surrounding healthy tissue and critical structures, minimizing the toxicities typically associated with conventional radiation therapy.

Nearly 24,000 patients have been treated with IRMdian. Currently, 53 MRI systems are installed in hospitals around the world where they are used to treat a wide variety of solid tumors and are the subject of many ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. For a list of treatment centers, please visit:


Nothing in this document is intended to provide specific medical advice or to replace written law or regulation.

Security statement

The MRIdian Linac system is not suitable for all patients, including those who are not candidates for magnetic resonance imaging. Radiation therapy can cause side effects that can vary depending on the part of the body being treated. The most common are usually temporary and may include, but are not limited to, irritation of the respiratory, digestive, urinary, or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, the side effects can be serious. Treatment sessions can vary in complexity and duration. Radiation therapy is not appropriate for all cancers. You should discuss the potential for side effects and their severity and the benefits of radiation therapy and magnetic resonance imaging with your doctor to make sure radiation therapy is right for you.

About ViewRay

ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® MRI-guided radiation therapy system. MRIdian is built on a proprietary high-definition MR imaging system designed from the ground up to meet the unique challenges and clinical workflow of advanced radiation oncology. Unlike MRI systems used in diagnostic radiology, MRIdian’s high-definition MRI has been specifically designed to address specific challenges including beam distortion, skin toxicity, and other issues that can arise when high magnetic fields interact with beams of radiation. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, among other things, ViewRay’s financial forecast for the full year 2022, expected future orders, expected future operational and financial performance, treatment outcomes, therapy uptake, innovation and performance of MRIdian systems. Actual results could differ from those projected in the forward-looking statements due to many factors. These factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay’s products, ability to convert backlog into revenue, timing of delivery of ViewRay’s products, timing, and the severity of the COVID-19 pandemic, including its impacts on our on-demand business, global operations and supply chains, results and other uncertainties associated with clinical trials, the ability to raise additional necessary funds to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with the development of new products or technologies, competition in the industry in which ViewRay operates and general market conditions. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business generally, see ViewRay’s current and future reports filed with of the Securities and Exchange Commission, including its annual report on Form 10-K for the fiscal year ended December 31, 2021 and its quarterly reports on Form 10-Q, updated periodically along with the company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay undertakes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. , except as required by law.


Show original content:

SOURCE ViewRay, Inc.

Comments are closed.